Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1Dermatologic 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Melanoma 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Capecitabine 124Temozolomide 123Specimen Handling 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × arsenous acid × Clear all
NCT01014546 2022-07-22

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Roswell Park Cancer Institute

Phase 1 Terminated
5 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00571116 2019-08-07

Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy

University of California, Irvine

Phase 1 Terminated
9 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡